Positive Results from NXP002 Pilot Study in Lung and Liver Fibrosis

31st January 2018

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces a positive outcome following innovative pilot studies in multiple fibrotic diseases for its NXP002 programme. Download News

Back to all News